Bellon Christine 4

What Happened
Christine Bellon, Chief Legal Officer of Beam Therapeutics (BEAM), was granted 20,000 restricted stock units (RSUs) on March 31, 2026. The award is reported as 20,000 shares at $0.00 (award/grant, code A), so there was no cash exchanged at grant. The RSUs represent the contingent right to receive one share of BEAM common stock per RSU and have a total reported acquisition value of $0 at grant.

Key Details

• Transaction date: 2026-03-31; Grant type: Award (A) — 20,000 RSUs @ $0.00.
• Filing date: 2026-04-02 (filed timely following the March 31 grant).
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: RSUs granted under the Beam Therapeutics 2019 Equity Incentive Plan. Vest in four substantially equal installments on each of the first four anniversaries of the grant, contingent on continued service. Each RSU converts to one share upon vesting.
• No 10b5-1 plan, sale, or tax-withholding details were disclosed in the filing.

Context
RSU grants are common executive compensation and do not involve immediate cash outlay or share sales. Because these RSUs vest over four years, they indicate potential future equity-based compensation rather than an immediate market transaction; the ultimate economic value will depend on BEAM's share price at each vesting date.